Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
COMMENTARY
Sumitomo Dainippon Aims at 100 Billion Yen Sales from “Frontier Business,” Making Challenge Beyond Drugs
A growing number of drug makers are attempting to diversify their businesses by expanding into non-pharmaceutical sectors. Sumitomo Dainippon Pharma, which is one of these companies, aims to establish its “frontier business” as a growth engine of its midterm business…
To read the full story
Related Article
- Sumitomo Dainippon Predicts 20-30 Billion Yen Sales from “Frontier Business” by FY2027
September 10, 2021
- Sumitomo Dainippon Eyes 100 Billion Yen Sales from Frontier Biz: President
August 7, 2020
- Sumitomo Dainippon, Save Medical Link Up on Diabetes App; Approval Eyed in FY2022
August 6, 2020
- Sumitomo Dainippon, Aikomi Join Forces for Research on Medical Devices to Relieve BPSD
February 12, 2019
COMMENTARY
- Survodutide Could Carve Out Role in MASH as Next-Gen Dual Agonist
September 28, 2026
- Regional Formularies Gain Ground, Raising Stakes for Drug Makers, Wholesalers
September 15, 2026
- As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
September 7, 2026
- Pharma Faces Wage Challenge in 5% Era as Industry Sustainability at Stake
September 3, 2026
- Beyond Dupixent: Next Wave of COPD Biologics Takes Shape
August 25, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…